Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4202111 | 0.87 | KCNH2 (1.00) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| SCHEMBL4206117 | 0.87 | KCNH2 (1.00) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL4358406 | 0.86 | KCNH2 (0.98) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| SCHEMBL9654030 | 0.85 | ADRB1 (0.82) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| SCHEMBL11251345 | 0.81 | ADRB2 (0.71) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| SCHEMBL8781201 | 0.79 | ADRB1 (0.83) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| SCHEMBL8588458 | 0.77 | ADRB1 (0.71) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| SCHEMBL7368283 | 0.76 | ADRB2 (0.65) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| SCHEMBL2024023 | 0.76 | ADRB2 (0.70) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 | |
| SCHEMBL2024020 | 0.76 | ADRB2 (0.70) | KCNH2SLC6A2SLC6A3ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| WO-2009137843-A2 | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | EMORY UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | KCNH2 469/4885SLC6A2 106/4885SLC6A3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.